Eli Lilly started providing patients with doses of its potential coronavirus vaccine in what it said was the world's first study of a potential antibody to the global disease.
The company said its LY-CoV555 treatment, which could create antibody therapies for the prevention and treatment of COVID-19, was given to patients as part of early-stage trials at the NYU Grossman School of Medicine in New York and Cedars-Sinai Medical Center in Los Angeles.
"Antibody therapies such as LY-CoV555 may have potential for both prevention and treatment of COVID-19 and may be particularly important for groups hardest hit by the disease such as the elderly and those with compromised immune systems," said Dr. Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer.
"Later this month, we will review the results of this first human study and intend to initiate broader efficacy trials. At the same time as we are investigating safety and efficacy, we also are starting large-scale manufacturing of this potential therapy," he added. "If LY-CoV555 becomes part of the near-term solution for COVID-19, we want to be ready to deliver it to patients as quickly as possible, with the goal of having several hundred thousand doses available by the end of the year."
So, what does this mean for the overall fight against coronavirus?
Jim Cramer said, however, that he's still focused on Regeneron.